Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Ashinskiy Metallurgical Plant intends to leave the stock exchange

5/23/23 AMEZ

Fesco started to transport cargo through the Indian port of Mundra

5/23/23 FESH

VKontakte launches NFT for the 320th anniversary of Saint Petersburg

5/23/23 VKCO

Tinkoff started issuing UnionPay cards

5/23/23 T

MD Medical Group exits from London Stock Exchange

5/23/23 MDMG

Rosseti South reported for 3 months of 2023 by IFRS

5/23/23 MRKY

Alrosa may not be able to replenish its mineral resource base

5/23/23 ALRS

Rusagro expects to work out a decision on redomiciliation in the coming months

5/23/23 RAGR

VK game engine was named Nau Engine

5/22/23 VKCO

Shareholders of Krasnoyarskenergosbyt approved dividends for 2022

5/22/23 KRSB